We have identified 21 different alpha-galactosidase A gene (GLA) mutations in 22 unrelated Czech and Slovak families with Fabry disease. Eleven of these mutations were novel (point mutations D93N, A135V, D155H, G171R, Q280K, G360S, Q330X, splicing errors c.194ins14, c.801ins36 and deletions c.674_732del59, g.3405_6021del2617). Genotyping of family members for family-specific mutations revealed 55 heterozygotes that manifested clinical symptoms of different severity. To examine the contribution of X-inactivation skewing to disease manifestation in Fabry heterozygotes, we have adopted the Mainz severity scoring scheme and compared the score values with the X-inactivation status in 39 carriers in an age-dependent manner. The age-score trendline of Fabry females who had a predominantly inactivated X-chromosome bearing a wild-type GLA allele (10 of 38 females) was markedly steeper than in the rest of the cohort. One female carrier with an inactivated mutated allele had a low score value when compared to the other heterozygotes of the same age. These data suggest that X-inactivation is indeed a major factor determining the severity of clinical involvement in Fabry heterozygotes. There was a statistically significant difference between the severity score values of heterozygotes with random and non-random X-chromosome inactivation at the 5% level of significance. Further studies will show if the degree of the wildtype allele inactivation will be useful as a predictive marker of severity of phenotype in Fabry heterozygotes. Although the correlation between X-inactivation skewing and presentation of the disease in Fabry heterozygotes has previously been suggested in the literature, this report is among the first attempts to examine this relationship systematically.

Institute of Inherited Metabolic Diseases 1st Faculty of Medicine Charles University Ke Karlovu 2 Prague 2 128 08 Czech Republic

See more in PubMed

Hum Mol Genet. 1993 Jul;2(7):1051-3 PubMed

Blood Cells Mol Dis. 1998 Dec;24(4):439-47 PubMed

Turk J Pediatr. 1995 Apr-Jun;37(2):125-40 PubMed

N Engl J Med. 1967 May 25;276(21):1163-7 PubMed

Clin Genet. 1991 Mar;39(3):233-7 PubMed

Am J Med Genet A. 2005 Apr 1;134A(1):84-7 PubMed

Clin Genet. 2004 Apr;65(4):299-307 PubMed

Hum Pathol. 1990 Oct;21(10):1067-73 PubMed

N Engl J Med. 1991 Feb 7;324(6):395-9 PubMed

Am J Hum Genet. 1990 Nov;47(5):784-9 PubMed

J Mol Biol. 2004 Mar 19;337(2):319-35 PubMed

Cell. 1984 Jan;36(1):131-8 PubMed

Hum Mutat. 2000;15(1):16-21 PubMed

J Med Genet. 1996 Aug;33(8):682-8 PubMed

Virchows Arch A Pathol Anat Histopathol. 1990;417(5):449-55 PubMed

Trends Genet. 1997 Mar;13(3):121-2 PubMed

Mol Genet Metab. 2003 Nov;80(3):307-14 PubMed

Am J Hum Genet. 1992 Dec;51(6):1229-39 PubMed

Hum Genet. 1992 Apr;89(1):29-32 PubMed

Electrophoresis. 1997 Dec;18(15):2714-23 PubMed

Anal Biochem. 1987 Apr;162(1):156-9 PubMed

Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 PubMed

J Soc Gynecol Investig. 2004 May;11(4):237-40 PubMed

Clin Chim Acta. 1981 May 5;112(2):247-51 PubMed

Mol Genet Metab. 2002 Sep-Oct;77(1-2):3-11 PubMed

J Med Genet. 2001 Nov;38(11):750-60 PubMed

Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations

The coincidence of IgA nephropathy and Fabry disease

The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations

Intravascular ultrasound assessment of coronary artery involvement in Fabry disease

Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy

Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients

Natural history of the respiratory involvement in Anderson-Fabry disease

The heart in Anderson-Fabry disease and other lysosomal storage disorders